David Picard

David Picard

Chief Executive Officer

David co-founded Moleac and has been serving as CEO since.

Prior to founding Moleac, David has spent ten years at the Boston Consulting Group (“BCG”) where he was a member of the worldwide Health Care Practice Area. He has worked both in Europe and in Asia. He has extensive experience in working in China and in Korea.

David graduated from the two top engineering schools in France, Ecole Polytechnique and Ecole Nationale Supérieure des Mines de Paris, where he majored in mathematics and economics. David also holds a French degree (“DESS”) in business law.

Michel Lazdunski

Chairman of Scientific Advisory Board

World-renowned specialist of pharmacology of ion channels, Prof. Michel Lazdunski has made internationally recognized contributions to basic and applied research in pharmacology and pathology. These range from understanding the mechanisms underlying antihypertensives, antidiabetics, and anesthetics, to the mechanisms of cerebral ischemia, cardiac arrhythmia, convulsions and pain perception.

Over the last 30 years, Prof. Lazdunski and his team have not only elucidated the molecular properties of the structure and functioning of ion channels, they have used a highly diverse and sophisticated pharmacological arsenal to shed new light on the role of these ion channels and other ion transport systems in a wide range of diseases and pathological conditions.

Prof. Michel Lazdunski received the CNRS Gold Medal, the highest French scientific distinction as well as the Jung Foundation Gold Medal for Science and Research. He has received other prestigious awards such as the Grand Prix of the French Academy of Sciences for biological research (Charles Leopold Mayer Prize), the International Society for Cardiac Research Prize, the Bristol-Myers Foundation Neuroscience Award, the Athena Foundation – Institut de France Prize, the Grand Prix of the French Academy of Sciences for research of importance to the medical field and the Grand Prix of the French Foundation for Medical Research.

Prof. Michel Lazdunski is a member of several academies, including the Academia Europaea and the French Academy of Sciences. He is also a member of the Belgian Academy of Medicine.

Herve D’Allens

Medical and Marketing Advisor

Graduating in clinical oncology and INSEAD young managers program, Hervé has worked, at Boots Pharma, managed clinical development at Glaxo France and prepared the introduction of new products at GSK. Prior to joining Moleac, he was director of new product management for Asia-Pacific and Strategic Support for Europe at Sanofi.

Robert Gan

Senior Medical Advisor

Dr. Robert Gan obtained his Doctor of Medicine degree from the University of the Philippines, after which he trained in Neurology at the University of Chicago and sub-specialized in Stroke at the Neurological Institute of New York/Columbia University with Professors Mohr and Sacco.

As a clinician and a researcher, Robert has focused on treating stroke patients and conducting clinical trials, initially at University of the Philippines where he was appointed clinical associate professor, then at the National Neuroscience Institute of Singapore where he spent 5 years before joining Lundbeck as a Regional Medical Manager and Clinical Research Scientist for a large scale international stroke study.

Claire Yim

Vice President, Commercial Development

Claire graduated from EM Lyon and started her career in Moleac in 2009 as a business development executive. She now oversees Moleac international sales in a large number of markets in South East Asia, Middle East and North Africa.

Nianmin Zhou

Alliances in China

Zhou Nianmin is the General Manager of Tang Frères I&M in Beijing and the general manager of several companies of Tang Frères in China. Nianmin was born in China and has worked with Tang Frères for more than 15 years both in China and in South East Asia. Nianmin has considerable experience in setting and developing businesses in China and Thailand.

Within Moleac, Nianmin drives the negotiation and the implementation of the scientific cooperation and commercial development agreements in China.

Jonathan Seow

Vice President, Chief Financial Officer

Prior to joining Moleac, Jonathan was an Associate Director in Corporate Finance and Business Development with Aslan Pharmaceuticals. He oversaw the successful completion of a US$42M Nasdaq IPO in 2018, and multiple follow-on offerings totalling more than US$125M. Prior to Aslan, he was in the investment banking and equity research industry, last serving as the lead analyst covering healthcare and consumer with CIMB.

Jonathan holds an MPhil in Management degree from the University of Cambridge, and graduated with a Bachelor of Commerce (First Class Honours) from the University of Western Australia as the top student and a Philip Brown scholar under the Jean Rogerson scholarship.

Hui Foong Mei

Vice President, Head of Regulatory Affairs & Quality Assurance

Foong Mei is a registered pharmacist graduated from National University of Singapore.

She had worked for the Health Sciences Authority (HSA) Singapore where she gained her pharmaceutical industry experience throughout a period of 15 years.

During her service with HSA, she assumed the post of the Deputy Head, Licensing and looked after pre-market evaluation of drug applications. She was then appointed to be the Head, Good Distribution Practice (GDP) Unit cum Senior GMP Auditor. Hence, she possesses vast audit experiences and is knowledgeable in GDP and PIC/S GMP requirements for pharmaceutical products.

Prior to joining Moleac in 2019, she was the Director, Complementary Health Product Branch. She led the HSA delegation in the ASEAN Traditional Medicines and Health Supplements Products Working Group (ASEAN TMHS PWG) meetings in the harmonization of quality and safety standards for TM and HS.

She is now leading the Regulatory Affairs and Quality Assurance team to ensure regulatory compliance and an effective quality management system for Moleac.

Emily Lim

Associate Vice President, Clinical Operations

Emily holds a Bachelor of Science in Life Sciences from National University of Singapore and subsequently graduate from NUS Academy of GxP Excellence (NUSAGE)-PAREXEL Postgraduate Certification in Clinical Trial Management. Before joining Moleac, Emily has clinical trial management experience in CRO companies and started her career with Moleac in 2018. Based in Singapore office, Emily oversees the operations of clinical trials and involves in the planning of Moleac’s Clinical Development Program.

Hui Juan Che

Associate Vice President, Chemistry, Manufacturing and Controls Production & quality Control Supply

Dr. Che received her PhD in Chemistry from the National University of Singapore. She has been working in the pharmaceutical and medical devices industry for 12 years, primarily specialized in R&D, Engineering, Quality Control and Manufacturing. Prior to joining Moleac, she had spent 5 years at Alcon Singapore, where she gained experience in cGMP compliance and QMS implementation. She is currently overseeing the group CMC (Chemistry Manufacturing & Controls), Quality Control and Supply Chain activities.

Ann Hards

Regulatory Affairs Consultant

Ann Hards received her PhD in Biophysics and Genetics from the University of Colorado in 1985. She has been involved in drug development since 1990, primarily strategizing and negotiating new drug approval in the employ of large pharma. During this period, she has had the responsibility for the worldwide (US, EU and +/- Japan) submission and prosecution of 6 new molecular entities and 7 major efficacy supplements resulting in 13 approvals. Included among these approvals are products with maximum annual sales of over 30 billion dollars including Lipitor®, Plavix®, Avapro®, etc. Dr Hards is currently working in the development of innovative biotechnology products including her consulting with Moleac

Shreeram (Ram) Agharkar, Ph.D.

Founder and President of Princeton Biopharma.Development Solutions ( PBDS) ,LLC.
Consultant for Moleac since 2014.

Ram started this consulting business after 38 years of successful career in Pharmaceutical R&D. He has excellent track record in pharmaceutical development and global registration of NCEs in many therapeutic areas. After receiving Ph.D. in Pharmaceutics from the University of Kansas, he joined Abbott laboratories, R&D in Chicago. He spent five years each at Abbott and Schering-plough before joining Bristol-Myers Squibb, R&D. He then joined Sanofi R&D as the global Vice President of Pharmaceutical development. During his 10.5 years at Sanofi he managed a large group of scientists in many countries. Dr. Agharkar is recognized as a global leader who ensures high performance with customer focus, scientific rigor and speed without compromising quality. He has published more than 25 scientific papers and holds 15 patents.